CN101559218B - Composition with function of increasing bone density - Google Patents
Composition with function of increasing bone density Download PDFInfo
- Publication number
- CN101559218B CN101559218B CN200910078091XA CN200910078091A CN101559218B CN 101559218 B CN101559218 B CN 101559218B CN 200910078091X A CN200910078091X A CN 200910078091XA CN 200910078091 A CN200910078091 A CN 200910078091A CN 101559218 B CN101559218 B CN 101559218B
- Authority
- CN
- China
- Prior art keywords
- compositions
- calcium carbonate
- bone density
- preparation
- chondroitin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000037182 bone density Effects 0.000 title claims abstract description 26
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 69
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 39
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 39
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 34
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 32
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 claims abstract description 31
- 229960001911 glucosamine hydrochloride Drugs 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 229960003563 calcium carbonate Drugs 0.000 claims abstract description 15
- 244000068988 Glycine max Species 0.000 claims description 33
- 235000010469 Glycine max Nutrition 0.000 claims description 33
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 33
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 33
- 235000008696 isoflavones Nutrition 0.000 claims description 33
- 229940071162 caseinate Drugs 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 13
- 229940023488 pill Drugs 0.000 claims description 11
- 239000006187 pill Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- 235000015091 medicinal tea Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007910 chewable tablet Substances 0.000 claims description 3
- 229940068682 chewable tablet Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 210000003022 colostrum Anatomy 0.000 claims description 2
- 235000021277 colostrum Nutrition 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 235000021262 sour milk Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 239000005018 casein Substances 0.000 abstract description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 2
- 235000021240 caseins Nutrition 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 235000003687 soy isoflavones Nutrition 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 241000700159 Rattus Species 0.000 description 12
- 210000000988 bone and bone Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000000689 upper leg Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- -1 amino polysaccharide Chemical class 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 229960002442 glucosamine Drugs 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001009 osteoporotic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000055008 Matrilin Proteins Human genes 0.000 description 2
- 108010072582 Matrilin Proteins Proteins 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SDOFMBGMRVAJNF-SLPGGIOYSA-N (2r,3r,4r,5s)-6-aminohexane-1,2,3,4,5-pentol Chemical compound NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SDOFMBGMRVAJNF-SLPGGIOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010582 Congenital osteodystrophy Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000007652 Dysostoses Diseases 0.000 description 1
- 201000001324 Dysostosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004120 green S Substances 0.000 description 1
- 235000012701 green S Nutrition 0.000 description 1
- WDPIZEKLJKBSOZ-UHFFFAOYSA-M green s Chemical compound [Na+].C1=CC(N(C)C)=CC=C1C(C=1C2=CC=C(C=C2C=C(C=1O)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](C)C)C=C1 WDPIZEKLJKBSOZ-UHFFFAOYSA-M 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000002490 spark plasma sintering Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Abstract
The invention relates to a composition with a function of increasing bone density and a preparation method thereof. Active components comprised by the composition are calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, casein phosphopeptide, and soy isoflavone. The composition is prepared by reasonably and scientifically matching and combining the raw materials, and is prepared intooral preparations which are convenient to take. Experiments prove that the composition has the function of increasing the bone density.
Description
Technical field
The present invention relates to a kind of composition and method of making the same, belong to the health food technology field with bone density improving function.
Background technology
Osteoporosis is a kind of skeletal diseases of general, is characterized in osteopenia, and the fine structure of osseous tissue is destroyed, and the fragility of bone is increased, and the danger of fracture increases.It can make except that head the skeleton at any position fracture.Because the aging of world population is even osteoporosis and osteopenia also are common metabolic osteopathy in developed country.Medical circle will have been prevented and treated osteoporosis, the prevention fracture is placed on position of equal importance with treatment hyperlipidemia, prevention myocardial infarction, treatment hypertension prevention apoplexy.According to incompletely statistics, the senile osteoporosis disease sickness rate of China more than 60 years old is about 59.89%, bone density improving, effectively treats the important topic that osteoporosis has become people's extensive concern.
Osteoporosis be one worldwide, more and more cause the health problem that people pay attention to.About 200,000,000 people in the whole world suffer from osteoporosis at present, and its sickness rate has leapt to commonly encountered diseases, frequently-occurring disease the 7th.Current research shows that in fact the osteoporosis in that China is considered to the peculiar disease of old people always just exists in the Childhood.Up to now, still do not have a kind of safe and effective method to make the skeleton after loosening recover normal bone amount and structure fully, therefore improve people, understand its pathogenic factors, strengthen early prevention and seem particularly important the dangerous understanding of osteoporosis.
Prevent or reduce the generation of primary disease, people take certain intervening measure just to seem very necessary except strengthening self health consciousness, making great efforts to form the good living habit.Health food has certain health care, and safe, can take for a long time, can satisfy the demand of people's daily health caring again, therefore, the exploitation bone density improving health food be with a wide range of applications.This product also can significantly reduce the risk factor that current sickness rate is high, the morbidity crowd is wide, have a strong impact on the osteoporosis disease of human health and quality of life in bone density improving, can strengthen the meaning and the value of osteoporosis early prevention greatly.
Summary of the invention
Based on above-mentioned situation, the object of the present invention is to provide a kind of compositions with bone density improving function; Another purpose provides the method for preparing of above-mentioned composition; Also be to provide the application of above-mentioned composition in preparation prevention or minimizing osteoporosis product.
The present invention realizes through following technical scheme:
A kind of compositions with bone density improving function; His contained active component is calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, soybean isoflavone; By weight, the active component of processing said composition is: calcium carbonate 5-15 part, glucosamine hydrochloride 4-12 part, chondroitin sulfate 2-6 part, phosphopeptide caseinate 3-7 part, soybean isoflavone 2-6 part; Preferably, by weight, calcium carbonate 8-12 part, glucosamine hydrochloride 6-10 part, chondroitin sulfate 3-5 part, phosphopeptide caseinate 4-6 part, soybean isoflavone 3-5 part; Particularly preferably be, by weight, the active component of processing said composition is: calcium carbonate 9-11 part, glucosamine hydrochloride 7-9 part, chondroitin sulfate 3.5-4.5 part, phosphopeptide caseinate 4.5-5.5 part, soybean isoflavone 3.5-4.5 part; Best of breed is 10 parts of calcium carbonate, 8 parts of glucosamine hydrochloride, 4 parts of chondroitin sulfate, 5 parts of phosphopeptide caseinates, 4 parts of soybean isoflavone.
Preparation of the present invention is an oral formulations; Comprise: hard capsule, soft capsule, granule, tablet, milk slice, sour milk tablet, colostrum sheet, chewable tablet, honeyed pill, concentrated honeyed pill, water-honeyed pill, condensed water honeyed pill, oral liquid, packed medicinal tea, decoction medicinal tea, beverage, powder, saccharide, medicated wine, preserve.
Described preparation also comprises adjuvant except that active component.
The preparation technology of described preparation comprises: get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, soybean isoflavone, sieve, add acceptable accessories, mixing is prepared into required oral formulations by common process.
The method for preparing of described tablet is: get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, soybean isoflavone, cross 80 mesh sieves respectively, add filler, mix; Add wetting agent, granulate drying, granulate; Add lubricant, mix tabletting; Coating, packing gets tablet.
The present composition has the function of bone density improving, is used for the application at preparation prevention or minimizing osteoporosis or relevant disease product.
Active component of the present invention all is commercially available or is prepared from according to the character of each active component.
Osteoporosis is impaired with the osseous tissue microstructure, and bone ore deposit composition and bone matrix equal proportion ground constantly reduce, the sclerotin attenuation, and bone trabecula quantity reduces, the disease of a kind of whole body dysostosis that increase of bone fragility and risk of fractures degree raise.It is many-sided producing osteoporotic reason, comprising heredity, life style, nutriture, disease and medicine etc.
These article are in the osteoporotic generation reason of analysis-by-synthesis; Osteoporosis symptom, osteoporosis crowd's situation; And be foundation with modern pharmacology research; Form improve bone density or help the effect of calcium absorption of the equal tool of each active component in conjunction with the functional characteristics prescription of chemistry that is mainly used in osteoporotic conditions at present and natural product.
Growth promoter and the metabolism of calcium to keeping human body; Keep, adjust the normal excitement of N&M; The division of cell; The activation of enzyme; Solidifying of blood; Endocrine activity and people's thinking activities or the like physiological function is significant.
In forming active component of the present invention, Maalox Antacid in can generate the solubility calcium ion during with gastric acid and blood calcium is risen by intestinal absorption.Because of its calcium content is high, have no side effect the calcium complement agent of the best that be to use the most extensively, calcium content is the highest, effective, price is low.
Glucosamine is a kind of natural amino monosaccharide, is present in human body particularly in the articular cartilage, is the base substance of synthesizing amino polysaccharide, also is the constituent of proteoglycan in the articular cartilage.It can act on articular cartilage specifically, recovers the normal metabolic function of chondrocyte, stimulates the proteoglycan that chondrocyte produces has normal polymer structure, safeguards the morphosis of cartilage matrix; Suppress the generation of ultra oxyradical, collagenase and the phospholipase A2 of damage cartilage matrix II Collagen Type VI; Suppress the synthetic of prostaglandin, various harmful substances such as protection 17-hydroxy-11-dehydrocorticosterone are to the destruction of chondrocyte, thereby delay the pathological process and the PD of bone property articular degeneration, improve joint motion, alleviating pain.The total trend of glucosamine drug study shows that glucosamine can improve the symptom of osteoarthritis; Promote the metabolic activity of articular cartilage to strengthen; The anabolism of collagen, ammonia polyose of candy and other structural protein increases, and the protection and the reparation of articular cartilage had crucial meaning.
Chondroitin sulfate (CS) sodium salt and D-glucamine and D-galactose therapeutic alliance arthritis, but mitigation symptoms, its mechanism can be removed the Na+ in a large amount of absorption synovial membranes for CS, promotes bone matrix hyperplasia, makes destructive cartilage recover normal.But the CS of natural PHOSPHATIDYL ETHANOLAMINE derivatization avoids damage in natural joint cartilage surface protective tissue, and synthetic PECS is used in damaged part, simulates natural CSPG effect, can suppress the formation of pannus, the protection cartilaginous tissue.Chondroitin sulfate can be used for treatment early stage or moderate arthritis and non-evident effect; Explain that CS can promote osteoblastic hypertrophy, promote new bone formation, the process of accelerated bone healing.Oral CS can alleviate OA pain and improvement knee function, reduces the joint and corrodes progress.CS is a naturally occurring composition in the connective tissue, can be used for lubricated and support joint by bound water molecule, makes joint motion freely.
Phosphopeptide caseinate (CPP) derives from the peptide chain that is rich in phosphoserine in the casein; Has affinity with the calcium iron ion; Form soluble complexes; In whole small intestinal environment, keep dissolved state, can delay and stop the crystalline formation of insoluble phosphate significantly, thereby increase the calcium of small intestinal, the absorption of ferrum.
Soybean isoflavone (Isoflovone) is one type of secondary metabolite that Semen sojae atricolor forms in growth course, is a kind of in the biological flavone, and the estrogen of its structure and human secretory is quite similar, so justice is called as " phytoestrogen ".Soybean isoflavone can combine with estrogen receptor, shows two kinds of important BAs: estrogen activity and estrogen antagonist are active.For the low person of estrogen level; Soybean isoflavone shows as weak estrogen action; Combine with the estrogen receptor in the osteoblast, strengthen osteoblastic activity, promote generation, secretion and the bone mineralization process of bone matrix; But the generation of prevention of osteoporosis disease alleviates some simultaneously and estrogen level reduces diseases associated.
In sum, active component of the present invention all has the bone density of raising or helps the theoretical foundation of calcium absorption abundant, and each active component compatibility is used, and can improve the absorption of human body to calcium, bone density improving.Show that through pharmacological toxicology research this compositions is safe and reliable in addition, the effect that improves bone density is arranged, with strong points, effective.Simultaneously, the present invention fills a prescription rationally, and meets State Food and Drug Administration's healthy food material use regulation.
Below through experimental example beneficial effect of the present invention is described:
Experimental example:
1, main material
Animal: cleaning level Wistar female rats, body weight 249-299g.Provide by Military Medical Science Institute's Experimental Animal Center.
Feedstuff: referring to " bone density improving functional experiment method " preparation in the Ministry of Public Health " health food check and assessment technique standard " (version in 2003).
The present composition (recommended amounts: 3.2g/ people. day (53.3mg/kgBW)).
2, method and result
At first through rats by intraperitoneal injection 50mg/kgBW pentobarbital sodium solution anesthesia, in after portion's QUMAO carries out partly sterilised with iodine tincture and ethanol again down, do 1cm left and right sides otch along the stomach wall median line and rat is implemented castration perform the operation the excision bilateral ovaries; It is the same but do not extract bilateral ovaries that other gets the operation of one group of rat, makes Sham-operated control group.
The postoperative animal is divided into high dose group (recommended amounts is 1599mg/kgBW for 30 times), middle dose groups (recommended amounts is 533mg/kgBW for 10 times) at random according to body weight; Low dose group (recommended amounts is 267mg/kgBW for 5 times), oophorectomize+solvent (contrast of castration model) group, calcium carbonate positive controls; Other establishes the sham-operation negative control group; Every group of single cage of 10 animals raised.High, medium and low dose groups is irritated stomach by design dosage with the 1ml/100gBW per os and is given the present composition; Sham-operation negative control and oophorectomize+solvent (contrast of castration model) group is irritated stomach with the equivalent deionized water; The calcium carbonate positive controls gives calcium carbonate, and dosage is that 408mg/kgBW is suitable with the high dose group calcium content.All laboratory animal is all drunk deionized water, weighs once 12 weeks of experimental period weekly.
Animal feeding sacrificed by decapitation after 12 weeks separates the right side femur, and 105 baking ovens dry to constant weight; The weighing bone is heavy; Use the bone mineral measuring instrument, measure the bone density of rat femur mid point and femur distal end, adopt wet method digestion; With the Z-2000 of Hitachi atomic absorption spectroscopy determination femur calcium content, the result sees 1-2.
Table 1 present composition is to the influence of rat femur weight and calcium content of bone (X ± s)
* compare P＜0.05 with the castration model control group
Visible by table 1, Sham-operated control group and castration model control group compare, and unit femur calcium content is apparently higher than the castration model control group, and difference has significance (P＜0.05), and the modeling success is described; Each dose groups and castration model control group compare, and the unit femur calcium content of high dose group and middle dose groups rat is significantly higher than castration model control group rat (P＜0.05).
Table 2 present composition is respectively organized relatively (X ± SD) of rat bone density and femur length
* compare P＜0.05 with the castration model control group
Visible by table 2, each dose groups of the present composition and castration model control group compare, and rat femur distal end bone density value, rat femur mid point bone density value (except the low dosage) etc. all is higher than castration model control group (P＜0.05); Each dose groups of the femur length present composition and castration model control group comparing difference do not have significance, have only sham operated rats to be lower than castration model control group (P＜0.05).
Consolidated statement 1, table 2, experimental result show that the present composition has the effect of bone density improving function.
Concrete embodiment
Below come further to set forth preparation of compositions method according to the invention through embodiment.
Embodiment 1:
Calcium carbonate 250g glucosamine hydrochloride 200g chondroitin sulfate 100g
Phosphopeptide caseinate 125g soybean isoflavone 100g magnesium stearate 4g dextrin 5g
30 POVIDONE K 30 BP/USP 3016g stomach dissolution type film coating material 40g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, cross 80 mesh sieves respectively, add dextrin, mix, add 30 POVIDONE K 30 BP/USP 3075% alcoholic solution and granulate, 16 mesh sieve granulate, granule is subsequent use; Take by weighing magnesium stearate by recipe quantity, cross 80 mesh sieves, mix, tabletting (the heavy 0.8g of sheet) with above-mentioned granule; Get stomach dissolution type film coating powder, be mixed with 8% 70% alcoholic solution, plain sheet is dropped into coating in the coating machine, promptly get tablet.
Wherein stomach dissolution type film coating material comprises hydroxypropyl emthylcellulose 31.6g, 2g polyethylene glycol 6000, Pulvis Talci 1.2g, titanium dioxide 1.2g, the edible green S of 4g.
Eating method and amount: every day 2 times, each 2.
Embodiment 2:
Calcium carbonate 375g glucosamine hydrochloride 300g chondroitin sulfate 50g
Phosphopeptide caseinate 175g soybean isoflavone 50g maltose alcohol 49g, sucralose 1g,
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, cross 80 mesh sieves respectively, mix, add maltose alcohol, sucralose, mixing, the 80-90% alcohol granulation, drying, packing promptly gets granule.
Embodiment 3:
Calcium carbonate 125g glucosamine hydrochloride 100g chondroitin sulfate 150g
Phosphopeptide caseinate 75g soybean isoflavone 150g pregelatinized Starch 130g
Micropowder silica gel 5g aspartame 15g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add the pregelatinized Starch of recipe quantity; Aspartame, mixing adds micropowder silica gel, mixing; Granulate, packing promptly gets granule.
Embodiment 4:
Calcium carbonate 200g glucosamine hydrochloride 250g chondroitin sulfate 75g
Phosphopeptide caseinate 150g soybean isoflavone 125g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add mannitol, the aspartame of recipe quantity, mixing is granulated, drying, and tabletting gets chewable tablet.
Embodiment 5:
Calcium carbonate 300g glucosamine hydrochloride 150g chondroitin sulfate 125g
Phosphopeptide caseinate 100g soybean isoflavone 75g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add adjuvant, conventional method is processed capsule.
Embodiment 6:
Calcium carbonate 225g glucosamine hydrochloride 175g chondroitin sulfate 112.5g
Phosphopeptide caseinate 112g soybean isoflavone 87.5g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add adjuvant, conventional method is processed milk slice.
Embodiment 7:
Calcium carbonate 275g glucosamine hydrochloride 225g chondroitin sulfate 87.5g
Phosphopeptide caseinate 138g soybean isoflavone 112.5g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add adjuvant, conventional method is processed pill.
Embodiment 7:
Calcium carbonate 210g glucosamine hydrochloride 180g chondroitin sulfate 87.5g
Phosphopeptide caseinate 137.5g soybean isoflavone 112.5g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add adjuvant, conventional method is processed packed medicinal tea.
Embodiment 8:
Calcium carbonate 250g glucosamine hydrochloride 200g chondroitin sulfate 100g
Phosphopeptide caseinate 125g soybean isoflavone 100g
Get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, the soybean isoflavone of recipe quantity, pulverize, sieve, add adjuvant, conventional method is processed oral liquid.
Claims (9)
1. compositions with bone density improving function; It is characterized in that; By weight, the active component of processing said composition is: calcium carbonate 5-15 part, glucosamine hydrochloride 4-12 part, chondroitin sulfate 2-6 part, phosphopeptide caseinate 3-7 part, soybean isoflavone 2-6 part.
2. compositions according to claim 1; It is characterized in that; By weight, the active component of processing said composition is: calcium carbonate 8-12 part, glucosamine hydrochloride 6-10 part, chondroitin sulfate 3-5 part, phosphopeptide caseinate 4-6 part, soybean isoflavone 3-5 part.
3. compositions according to claim 1 and 2; It is characterized in that; By weight, the active component of processing said composition is: calcium carbonate 9-11 part, glucosamine hydrochloride 7-9 part, chondroitin sulfate 3.5-4.5 part, phosphopeptide caseinate 4.5-5.5 part, soybean isoflavone 3.5-4.5 part.
4. according to any described a kind of compositions among the claim 1-3, it is characterized in that described preparation is an oral formulations with bone density improving function.
5. a kind of preparation according to claim 4 with compositions of bone density improving function; It is characterized in that described oral formulations is meant capsule, granule, tablet, pill, oral liquid, medicinal tea, beverage, powder, saccharide, medicated wine, preserve.
6. a kind of preparation with compositions of bone density improving function according to claim 5 is characterized in that capsule is meant hard capsule, soft capsule; Tablet is meant ordinary tablet, milk slice, sour milk tablet, colostrum sheet, chewable tablet; Pill is meant honeyed pill, concentrates honeyed pill, water-honeyed pill, condensed water honeyed pill; Medicinal tea is meant packed medicinal tea, decocts medicinal tea.
7. any described preparation of compositions method among the claim 1-3; It is characterized in that; Said preparation technology comprises: get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, soybean isoflavone, sieve, add acceptable accessories; Mixing is prepared into required oral formulations by common process.
8. preparation of compositions method according to claim 7 is characterized in that, described tablet is preparation like this: get calcium carbonate, glucosamine hydrochloride, chondroitin sulfate, phosphopeptide caseinate, soybean isoflavone, cross 80 mesh sieves respectively; Add filler, mix, add wetting agent, granulate; Drying, granulate adds lubricant, mixes; Tabletting, coating, packing gets tablet.
9. according to any described compositions among the claim 1-3, it is characterized in that described compositions is used for the application at preparation bone density improving product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910078091XA CN101559218B (en) | 2009-02-16 | 2009-02-16 | Composition with function of increasing bone density |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910078091XA CN101559218B (en) | 2009-02-16 | 2009-02-16 | Composition with function of increasing bone density |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101559218A CN101559218A (en) | 2009-10-21 |
| CN101559218B true CN101559218B (en) | 2012-05-30 |
Family
ID=41218311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910078091XA Active CN101559218B (en) | 2009-02-16 | 2009-02-16 | Composition with function of increasing bone density |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101559218B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240037A (en) * | 2010-05-13 | 2011-11-16 | 江苏星驰生物科技有限公司 | Amino acid and calcium composite powder |
| CN101966222A (en) * | 2010-09-26 | 2011-02-09 | 林晨伟 | Medicinal composition and preparation for strengthening bones and preparation method thereof |
| CN101999462A (en) * | 2010-10-12 | 2011-04-06 | 李国勇 | Milk powder for preventing and treating osteoporosis |
| CN102485734A (en) * | 2010-12-06 | 2012-06-06 | 张治平 | Compound for increasing bone mineral density and synthetic method thereof |
| CN102085356B (en) * | 2010-12-28 | 2013-02-27 | 北京同仁堂健康药业股份有限公司 | Composition for increasing bone mineral density and preparation method thereof |
| CN102133395B (en) * | 2011-03-18 | 2013-04-10 | 上海海维生物科技有限公司 | Skeleton health-care product or medicinal composite and application thereof |
| CN102178933B (en) * | 2011-04-20 | 2013-05-15 | 威海康博尔生物药业有限公司 | Preparation for preventing and treating osteoporosis and osteoarthrosis |
| CN102302116B (en) * | 2011-06-10 | 2013-11-27 | 营养屋(成都)生物医药有限公司 | Calcium supplementing and calcium locking health care food and preparation method thereof |
| CN103652545A (en) * | 2012-09-26 | 2014-03-26 | 郑州御寿堂健康产业科技发展有限公司 | Product used for bone diseases and preparation process thereof |
| CN104939054A (en) * | 2014-03-26 | 2015-09-30 | 营养屋(成都)生物医药有限公司 | Health food capable of enhancing bone mineral density and immunity and preparation method of health food |
| CN106138085A (en) * | 2015-03-25 | 2016-11-23 | 烟台宝备生物技术有限公司 | A kind of have medicine or the health food increasing bone density effect |
| CN106173614A (en) * | 2015-05-06 | 2016-12-07 | 北京宝德润生医药科技发展有限公司 | A kind of have compositions increasing bone substance density improving function and preparation method thereof |
| CN106729599B (en) * | 2015-11-25 | 2020-06-23 | 浙江爱生药业有限公司 | Pharmaceutical composition for increasing bone mineral density and preparation method and application thereof |
| CN105996052A (en) * | 2016-07-01 | 2016-10-12 | 福建省力菲克药业有限公司 | Healthcare food for improving bone mineral density and preparation method thereof |
| CN108815505B (en) * | 2018-07-01 | 2021-09-21 | 江西天元药业有限公司 | Composition for improving bone density and bone joint function of middle-aged and elderly people and avoiding lumbar and leg cramps |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314361C (en) * | 2003-04-02 | 2007-05-09 | 李安虎 | Joint healthy beverage or food and preparation thereof |
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
-
2009
- 2009-02-16 CN CN200910078091XA patent/CN101559218B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1314361C (en) * | 2003-04-02 | 2007-05-09 | 李安虎 | Joint healthy beverage or food and preparation thereof |
| CN101015682A (en) * | 2007-02-01 | 2007-08-15 | 甘肃奇正藏药有限公司 | Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101559218A (en) | 2009-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101559218B (en) | Composition with function of increasing bone density | |
| CN1903220B (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| JP2971579B2 (en) | Amino sugar and glycosaminoglycan compositions for the treatment and recovery of connective tissue | |
| CN102224896A (en) | Health food for enhancing human immunity and increasing bone mineral density and preparation method thereof | |
| US8728533B2 (en) | Composition comprising crustacean gastrolith components and its use | |
| CN102949710B (en) | Pharmaceutical composition or healthcare product for increasing bone mineral density and preparation method of pharmaceutical composition or healthcare product | |
| CN101695382A (en) | Calcium supplementing preparation with functions of improving bones and joints | |
| CN101711786B (en) | Preparation used for relieving osteoarthropathy and enhancing immunity | |
| CN101181294A (en) | Pharmaceutical composition for curing osteoarthritis | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN1947724A (en) | Compound amino-glucose hydrochloride, chondroitin sulfate effervescent, tablets prepn. method and use thereof | |
| CN102085356B (en) | Composition for increasing bone mineral density and preparation method thereof | |
| CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
| CN1823764A (en) | Medicinal composition containing strontium fuminate and vitamin D | |
| CN101455396A (en) | Nutrient health-care food capable of promoting bone and bone arthrosis health | |
| CN106177908A (en) | A kind of have compositions increasing bone substance density improving function and preparation method thereof | |
| CN110946994A (en) | Composition for increasing bone mineral density and preparation method thereof | |
| CN102626463A (en) | Natural medicine compound for increasing bone mineral density and preventing and treating osteoporosis | |
| CN105595327A (en) | Special calcium citrate preparation for astronauts | |
| WO2009087652A2 (en) | Pharmaceutical compositions of calcitriol and mineral supplements | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| CN102000110A (en) | Composition used for preventing or treating bone and joint diseases and preparation method thereof | |
| CN102626420B (en) | Mixed preparation containing strontium, calcium and vitamin D | |
| CN1907269A (en) | Aminoglucose composite effervescent preparation | |
| CN104587456A (en) | Production process for health product capable of increasing bone mineral density |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20091021 Assignee: Beijing Baode Runsheng Pharmaceutical Technology Development Co.,Ltd. Assignor: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Contract record no.: 2014110000034 Denomination of invention: Composition with bone mineral density addition function, and preparation method as well as application of composition Granted publication date: 20120530 License type: Exclusive License Record date: 20140620 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 100088 Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161222 Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3005 (Desheng Park) Patentee after: BEIJING BODYREVIVAL PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO.,LTD. Address before: 100088 Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |